Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.61 |
| ▸ | DHFR | P00374 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714702 | 0.86 | HRH4 (0.58) | HRH4DHFRHRH3CYP1A2CYP3A4 | |
| SCHEMBL7708544 | 0.83 | NOS1 (0.58) | DHFRHSD17B10 | |
| SCHEMBL4560009 | 0.83 | HRH4 (0.54) | HRH4DHFRHRH3CYP1A2CYP3A4 | |
| SCHEMBL7278447 | 0.78 | PTPN11 (0.59) | HRH4METCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30463625 | 0.77 | DHFR (0.56) | HRH4DHFRHTR3AHRH3 | |
| SCHEMBL7714603 | 0.77 | HRH4 (0.57) | HRH4HRH1HRH3 | |
| SCHEMBL2164938 | 0.77 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL27738433 | 0.77 | HRH4 (0.62) | HRH4HTR3AHRH2HRH1HRH3 | |
| SCHEMBL1032481 | 0.76 | HRH4 (1.00) | HRH4HTR3AHRH2HRH1HRH3 | |
| SCHEMBL2166254 | 0.75 | HRH4 (0.73) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885DHFR 1762/4885HTR3A 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.